<DOC>
<DOCNO>EP-0625903</DOCNO> 
<TEXT>
<INVENTION-TITLE>
TOPICAL ANTIGLAUCOMA COMPOSITIONS COMPRISING CARBONIC ANHYDRASE INHIBITORS AND BETA-BLOCKERS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2702	A61P4300	A61K3141	A61K31425	A61P4300	A61K3140	A61K31425	A61P2500	A61K3154	A61P2700	C07D51300	A61K3100	A61K3140	C07D33300	A61K4500	A61K3138	C07D49500	A61K3141	A61K3138	C07D33334	A61K3100	A61K3154	C07D51304	A61K4500	C07D49504	A61K4506	A61P2700	A61K31381	A61P2706	A61K31381	A61P2502	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61P	A61K	A61K	A61P	A61K	A61K	A61P	A61K	A61P	C07D	A61K	A61K	C07D	A61K	A61K	C07D	A61K	A61K	C07D	A61K	A61K	C07D	A61K	C07D	A61K	A61P	A61K	A61P	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P27	A61P43	A61K31	A61K31	A61P43	A61K31	A61K31	A61P25	A61K31	A61P27	C07D513	A61K31	A61K31	C07D333	A61K45	A61K31	C07D495	A61K31	A61K31	C07D333	A61K31	A61K31	C07D513	A61K45	C07D495	A61K45	A61P27	A61K31	A61P27	A61K31	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Ophthalmic pharmaceutical compositions useful in controlling elevated intraocular pressure associated with glaucoma and ocular hypertension are described. The compositions comprise a combination of a beta-blocker and a carbonic anhydrase inhibitor to reduce the production of aqueous humor, preferably formulated as a suspension having a pH between about 6.8 and about 7.8. These compositions may additionally contain a mucomimetic anionic polymer and/or a finely-divided drug carrier substrate to provide sustained release. A method of controlling elevated intraocular pressure with these compositions is also described.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ALCON LAB INC
</APPLICANT-NAME>
<APPLICANT-NAME>
ALCON LABORATORIES, INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DEAN THOMAS ROBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
DESANTIS LOUIS JR
</INVENTOR-NAME>
<INVENTOR-NAME>
DEAN, THOMAS ROBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
DESANTIS, LOUIS, JR.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This application is a continuation-in-part of U.S. Patent Application Serial No.
07/839,869, filed February 21, 1992.The present invention relates to the field of ophthalmology. In particular, the
invention relates to the treatment of glaucoma and associated elevations of intraocular
pressure and to the treatment of ocular hypertension associated with other diseases or
conditions.Although the underlying causes of glaucoma are not understood, its symptoms
often include elevated intraocular pressure, which may be caused either by over-production
or inadequate outflow of aqueous humor. If left untreated, or if
inadequately treated, glaucoma can lead to blindness or significant loss of vision.
There is therefore a continuing need for therapies which control the elevated
intraocular pressure associated with glaucoma.There are currently a number of drugs utilized in the treatment of glaucoma,
including: miotics (e.g., pilocarpine, carbachol and acetylcholinesterase inhibitors);
sympathomimetics (e.g., epinephrine, dipivalylepinephrine and para-amino clonidine);
beta-blockers (e.g., betaxolol, levobunolol and timolol); and carbonic anhydrase
inhibitors (e.g., acetazolamide, methazolamide and ethoxzolamide). Miotics and
sympathomimetics are believed to lower intraocular pressure ("IOP") by increasing the
outflow of aqueous humor, while beta-blockers and carbonic anhydrase inhibitors are
believed to lower IOP by decreasing the formation of aqueous humor. All four types
of drugs have potentially serious side effects. Miotics such as pilocarpine can cause
blurring of vision and other visual side effects, which may lead either to decreased
patient compliance or to termination of therapy. Carbonic anhydrase inhibitors can
also cause serious side effects which affect patient compliance and/or necessitate the
withdrawal of treatment. Moreover, at least one beta-blocker, timolol, has 
increasingly become associated with serious pulmonary side effects attributable to its
effect on beta-2 receptors in pulmonary tissue.A significant number of glaucoma patients require the administration of more
than one type of drug in order to achieve therapeutic control over their IOP. That is,
a single drug does not provide adequate control of IOP in these patients. Treatment
which includes the use of two or more of the above-cited classes of drugs requires the
patient to apply the compositions to the affected eye(s) in separate, spaced dosages
several times a day. Patient compliance with such complicated dosage regimens can
be very
</DESCRIPTION>
<CLAIMS>
A topical ophthalmic composition, comprising a
beta-blocker and a carbonic anhydrase inhibitor in an

ophthalmically acceptable vehicle, wherein the composition is a suspension and the
final composition pH is between about 5.0 and about 7.8 and

the carbonic anhydrase inhibitor has the formula:


or a pharmaceutically acceptable salt thereof, wherein:

R
1
 is:
H; C
1-4
 alkyl; C
2-4
 alkyl substituted optionally with OH, halogen, C
1-4
 alkoxy or
C(=O)R
7
;
R
2
 is:
H; C
1-8
 alkyl; C
2-8
 alkyl substituted with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy,
C
2-4
alkoxyC
1-4
alkoxy, OC(=O)R
7
, or C(=O)R
7
; C
3-7
 alkenyl unsubstituted or
substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy; C
3-7
 alkynyl
unsubstituted or substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy; C
1-3

alkyl substituted with phenyl or R
10
 either of which can be unsubstituted or
substituted optionally with C
1-3
 alkyl, C
1-3
 haloalkyl, OH, (CH
2
)
n
NR
5
R
6
,
halogen, C
1-4
 alkoxy, C
1-4
 haloalkoxy, C(=O)R
7
, S(=O)
m
R
8
 or SO
2
NR
5
R
6
,
wherein m is 0 - 2 and n is 0 - 2; C
2-4
 alkoxy substituted optionally with NR
5
R
6
,
halogen, C
1-4
 alkoxy, or C(=O)R
7
; phenyl or R
10
 either of which can be
unsubstituted or substituted optionally with C
1-3
 alkyl, C
1-3
 haloalkyl, OH,
(CH
2
)
n
NR
5
R
6
, halogen, C
1-4
 alkoxy, C
1-4
 haloalkoxy, C(=O)R
7
, S(=O)
m
R
8
 or
SO
2
NR
5
R
6
, wherein m is 0 - 2 and n is 0 - 2; provided that R
1
 and R
2
 cannot
both be H; or R
1
 and R
2
 can be joined to form a saturated ring of 5 or 6
atoms selected from O, S, C or N, such as, pyrrolidine, oxazolidine,

thiomorpholine, thiomorpholine, 1,1 dioxide, morpholine, piperazine,
thiazolidine 1,1 dioxide, or tetrahydrooxazine, which can be unsubstituted or

substituted optionally on carbon with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy, 
C(=O)R
7
, C
1-6
 alkyl, C
1-6
 alkyl substituted optionally with OH, NR
5
R
6
, halogen,
C
1-4
 alkoxy, C(=O)R
7
 or on nitrogen with NR
5
R
6
, C
1-4
 alkoxy, C(=O)R
7
, C
1-6

alkyl or C
2-6
 alkyl substituted optionally with OH, NR
5
R
6
, ,halogen C
1-4
 alkoxy
or C(=O)R
7
;
R
3
 is:
H; halogen; C
1-4
 alkyl; C
1-8
 alkoxy; C
1-8
 alkylthiol; C
2-8
 alkoxy substituted
optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy or C(=O)R
7
; C
1-4
 alkyl
substituted optionally with R
4
; or R
1
 and R
3
 can be joined together with carbon
atoms to form a ring of from 5 to 7 members in which said carbon atoms can

be unsubstituted or substituted optionally with R
4
;
R
4
 is:
OH; C
1-4
 alkyl unsubstituted or substituted optionally with OH, NR
5
R
6
,
halogen, C
1-4
 alkoxy, or C(=O)R
7
; C
1-4
 alkoxy; C
2-4
 alkoxy substituted optionally
with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy or C(=O)R
7
; NR
5
R
6
; phenyl or R
10

either of which can be unsubstituted or substituted optionally with OH,
(CH
2
)
n
NR
5
R
6
, halogen, C
1-4
 alkoxy, C
1-4
 haloalkoxy, C(=O)R
7
, S(=O)
m
R
8
 or
SO
2
NR
5
R
6
, wherein m is 0 - 2 and n is 0 - 2;

Provided that when G is SO
2
 and R
3
 is in the 4 position and is H or halogen then R
1

and R
2
 are not H, C
1-6
 alkyl substituted optionally with OH, C
1-6
 alkoxy, C
2-6

alkoxycarbonyl, C
2-6
 alkenyl, phenyl, phenoxy, pyridyl, tetrahydrofuryl, C
2-6

alkanoyl, C
2-6
 alkenyl, nor are they joined to form a 5, 6 or 7 member ring,
saturated or unsaturated, comprised of atoms selected optionally from C, O, S,

N in which said nitrogen when saturated, is substituted optionally with H or
C
1-6
 alkyl or in which said carbon is substituted optionally with C
1-6
 alkyl, C
1-6

alkoxy or OH; and when R
3
 is in the 5 position and is H, Cl, Br, or C
1-3
 alkyl
then neither R
1
 nor R
2
 can be H or C
1-4
 alkyl; and when G is C(=O) and in
the 5- position and R
3
 is H, then R
1
 and R
2
 cannot both be CH
3
;

R
5
 
&
 R
6
are the same or different and are: H; C
1-4
 alkyl; C
2-4
 alkyl substituted
optionally with OH, halogen, C
1-4
 alkoxy or C(=O)R
7
; C
1-4
 alkoxy; C
2-4
 alkoxy
substituted optionally with OH, halogen, C
1-4
 alkoxy or C(=O)R
7
; C
3-7
 alkenyl
unsubstituted or substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy; C
3-7

alkynyl unsubstituted or substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy;
C
1-2
alkyl-C
3-5
cycloalkyl; C(=O)R
7
 or R
5
 and R
6
 can be joined to form a ring of 
5 or 6 atoms selected from O, S, C or N, such as, pyrrolidine, oxazolidine,

thiomorpholine, thiomorpholine 1,1 dioxide, morpholine, piperazine or
thiazolidine 1,1-dioxide, which can be unsubstituted or substituted optionally on

carbon with OH, (=O), halogen, C
1-4
 alkoxy, C(=O)R
7
, C
1-6
 alkyl, C
1-6
 alkyl
substituted optionally with OH, halogen, C
1-4
 alkoxy, C(=O)R
7
 or on nitrogen
with C
1-4
 alkoxy, C(=O)R
7
, S(=O)
m
R
8
, C
1-6
 alkyl or C
2-6
 alkyl substituted
optionally with OH, halogen, C
1-4
 alkoxy, C(=O)R
7
 or on sulfur by (=O)
m
,
wherein m is 0 - 2;
R
7
 is:
C
1-8
 alkyl; C
1-8
 alkyl substituted optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy
or C(=O)R
9
; C
1-4
 alkoxy; C
2-4
 alkoxy substituted optionally with OH, NR
5
R
6
,
halogen or C
1-4
 alkoxy; NR
5
R
6
; or phenyl or R
10
 either of which can be
substituted or substituted optionally with OH, halogen, C
1-3
 alkyl, C
1-3

haloalkoxy, (CH
2
)
n
NR
5
R
6
, S(=O)
m
R
8
 or SO
2
NR
5
R
6
, wherein n is 0 or 1 and m
is 0-2;
R
8
 is:
C
1-4
 alkyl; C
2-4
 alkyl substituted optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy
or C(=O)R
7
;
R
9
 is:
C
1-4
 alkyl; C
1-4
 alkoxy; amino, C
1-3
 alkylamino, or di-C
1-3
 alkylamino;
R
10
 is:
a monocyclic ring system of 5 or 6 atoms composed of C, N, O, and/or S, such
as furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole,

isoxazole, isothiazole, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, and
pyrazine; and
G is:
C (=O) or SO
2
 or
wherein
the carbonic anhydrase inhibitor is (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno[2,3-b]thiopyran-2-sulfonamide

7,7-dioxide.
The composition of claim 1, wherein the carbonic anhydrase inhibitor is
selected from the group consisting of: (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-ethylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-propylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxy)propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; 
(R)-3,4-Dihydro-2-(3-methoxy)propyl-4-propylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-[2-methoxyethoxy)ethyl]
-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-3,4-Dihydro-2-[2-methoxyethoxy)ethyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-[3-(2-methoxy)ethoxy]propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-3,4-Dihydro-2-[3-(methoxyethoxy)propyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino--2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide;

(R)-3,4-Dihydro-4-ethylamino-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-4-Ethylamino-2-(4-methoxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide;

(R)-4-Ethylamino-2-(4-hydroxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenylmethyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenylmethyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide;

(R)-4-Ethylamino-3,4-dihydro-2-(2-methylpropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(6-hydroxyhexyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-3,4-Dihydro-2-(3-hydroxypropyl)-4-(2-methylpropyl)amino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; and (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]
thiopyran-2-sulfonamide
7,7-dioxide. 
The composition of claim 2, wherein the carbonic anhydrase inhibitor is
selected from the group consisting of: (R)-3,4-Dihydro-4-ethylamine-2-(3-methoxy)propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide

and (R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]thiopyran-2-sulfonamide

7,7-dioxide.
The composition of claim 1, wherein the carbonic anhydrase inhibitor is
selected from the group consisting of: (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-ethylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-propylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxy)propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride;
(R)-3,4-Dihydro-2-(3-methoxy)propyl-4-propylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2-[2-methoxyethoxy)ethyl]
-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide
hydrochloride: (R)-3,4-Dihydro-2-[2-methoxyethoxy)ethyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride: (R)-3,4-Dihydro-4-ethylamino-2-[3-(2-methoxy)ethoxy]propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-[3-(methoxyethoxy)propyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride;
(R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino--2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride;

(R)-3,4-Dihydro-4-ethylamino-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 

1,1-dioxide;
(R)-4-Ethylamino-2-(4-methoxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride;

(R)-4-Ethylamino-2-(4-hydroxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride;
(R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenylmethyl)-2H-thieno[3,2-e]
-1,2
thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenylmethyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide

hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(2-methylpropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(6-hydroxyhexyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride;
(R)-3,4-Dihydro-2-(3-hydroxypropyl)-4-(2-methylpropyl)amino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride hemihydrate; and (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]
thiopyran-2-sulfonamide
7,7-dioxide.
The composition of claim 4, wherein the carbonic anhydrase inhibitor is
selected from the group consisting of: (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxy)propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride

and (R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-dihydro-2(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]thiopyran-2-sulfonamide

7,7-dioxide.
The composition of any of claims 1 to 5, wherein the
final composition concentration of beta-blocker is less than

or equal to about 2.0 wt%, and the final composition
concentration of carbonic anhydrase inhibitor is less than or

equal to about 5 wt%. 
The composition of claim 6, wherein the final composition concentration of the
beta-blocker is between about 0.1 and about 1.0 wt%.
The composition of claim 7, wherein the final composition concentration of the

beta-blocker is between about 0.25 and about 0.5 wt%.
The composition of claim 8 wherein the final composition concentration of the
beta-blocker is 0.25 wt%.
The composition of claim 6, wherein the final composition concentration of the
carbonic anhydrase inhibitor is between about 0.25 and about 3 wt%.
The composition of claim 10, wherein the final
composition concentration of the carbonic anhydrase inhibitor

is between about 0.5 and about 2 wt.%.
The composition of any of claims 1 to 11, wherein the
beta-blocker is selected from the racemic and enantiomeric

forms of: betaxolol, timolol, metoprolol, befunolol,
falintolol, levobunolol, carteolol, mepindolol, pindolol,

bisoprolol, bopindolol, atenolol, arotinolol, acebutolol,
nadolol, celiprolol, metipranolol, bevantolol, ICI 118,551,

pamatolol, penbutolol, toliprolol, tiprenolol, practolol,
procinolol, exaprolol, cicloprolol, carazolol, tazolol,

tienoxolol, oxprenolol, propranolol, IPS 339, labetolol,
dilevalol, esmolol, bupranolol, bunolol, isoxaprolol,

diacetolol, hydroxylevobunolol, carvedilol, and their
pharmaceutically acceptable salts.
The composition of claim 12, wherein the beta-blocker is selected from the
racemic and enantiomeric forms of: betaxolol, timolol, carteolol, levobunolol and

hydroxylevobunolol, and their pharmaceutically acceptable salts.
The composition of claim 13, wherein the beta-blocker is betaxolol or a
pharmaceutically acceptable salt thereof. 
The composition of claim 13, wherein the beta-blocker is S-timolol or a
pharmaceutically acceptable salt thereof.
The composition of any of claims 1 to 11, wherein the
beta-blocker is a thiadiazole of formula:



and optically active isomers and pharmacologically acceptable salts thereof, wherein
R'' is selected from the group consisting of: hydrogen, halogen, C
1-5
 alkyl, C
2-5
 mono-alkenyl,
C
2-5
 alkoxy, C
3-6
 cycloalkyl, phenyl, phenalkyl, morpholino, furyl, thienyl and
pyrryl.
The composition of c!aim 16, wherein R'' is selected from the group consisting
of: chlorine, ethyl, allyl, cyclopropyl, ethoxy, phenyl, phenyl-chloromethyl and 2-(cyclopropylmethoxy)ethyl.
The composition of any of claims 1 to 17, further
comprising an anionic mucomimetic polymer wherein the final

composition concentration of the anionic mucomimetic polymer
is between about 0.05 and about 8.0 wt%.
The composition of claim 18 ,further comprising a finely-divided drug carrier
substrate, wherein the final composition concentration of the finely-divided drug

carrier substrate is between about 0.05 and about 10.0 wt%.
A composition according to any of claims 1 to 19 for use
in the treatment of glaucoma and ocular hypertension. 
Use of a composition comprising a beta-blocker and a
carbonic anhydrase inhibitor in an ophthalmically acceptable

vehicle, wherein: the final composition concentration of the
beta-blocker is less than or equal to about 2.0 wt%, and the

final composition concentration of the carbonic anhydrase
inhibitor is less than or equal to about 5 wt% and the

carbonic anhydrase inhibitor has the formula:


or a pharmaceutically acceptable salt thereof, wherein:

R
1
 is:
H; C
1-4
 alkyl; C
2-4
 alkyl substituted optionally with OH, halogen, C
1-4
 alkoxy or
C(=O)R
7
;
R
2
 is:
H; C
1-8
 alkyl; C
2-8
 alkyl substituted with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy,
C
2-4
alkoxyC
1-4
alkoxy, OC(=O)R
7
, or C(=O)R
7
; C
3-7
 alkenyl unsubstituted or
substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy; C
3-7
alkynyl
unsubstituted or substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy; C
1-3

alkyl substituted with phenyl or R
10
 either of which can be unsubstituted or
substituted optionally with C
1-3
 alkyl, C
1-3
 haloalkyl, OH, (CH
2
)
n
NR
5
R
6
,
halogen, C
1-4
 alkoxy, C
1-4
 haloalkoxy, C(=O)R
7
, S(=O)
m
R
8
 or SO
2
NR
5
R
6
,
wherein m is 0 - 2 and n is 0 - 2; C
2-4
 alkoxy substituted optionally with NR
5
R
6
,
halogen, C
1-4
 alkoxy, or C(=O)R
7
; phenyl or R
10
 either of which can be
unsubstituted or substituted optionally with C
1-3
 alkyl, C
1-3
 haloalkyl, OH,
(CH
2
)
n
NR
5
R
6
, halogen, C
1-4
 alkoxy, C
1-4
 haloalkoxy, C(=O)R
7
, S(=O)
m
R
8
 or
SO
2
NR
5
R
6
, wherein m is 0 - 2 and n is 0 - 2; provided that R
1
 and R
2
 cannot
both be H; or R
1
 and R
2
 can be joined to form a saturated ring of 5 or 6
atoms selected from O, S, C or N, such as, pyrrolidine, oxazolidine,

thiomorpholine, thiomorpholine 1,1 dioxide, morpholine, piperazine, 
thiazolidine 1,1 dioxide, or tetrahydrooxazine, which can be unsubstituted or

substituted optionally on carbon with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy,
C(=O)R
7
, C
1-6
 alkyl, C
1-6
 alkyl substituted optionally with OH, NR
5
R
6
, halogen,
C
1-4
 alkoxy, C(=O)R
7
 or on nitrogen with NR
5
R
6
, C
1-4
 alkoxy, C(=O)R
7
, C
1-6

alkyl or C
2-6
 alkyl substituted optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy
or C=(=O)R
7
;
R
3
 is:
H; halogen; C
1-4
 alkyl; C
1-8
 alkoxy; C
1-8
 alkylthiol; C
2-8
 alkoxy substituted
optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy or C(=O) R
7
; C
1-4
 alkyl
substituted optionally with R
4
; or R
1
 and R
3
 can be joined together with carbon
atoms to form a ring of from 5 to 7 members in which said carbon atoms can

be unsubstituted or substituted optionally with R
4
;
R
4
 is:
OH; C
1-4
 alkyl unsubstituted or substituted optionally with OH, NR
5
R
6
,
halogen, C
1-4
 alkoxy or C(=O)R
7
; C
1-4
 alkoxy; C
2-4
 alkoxy substituted optionally
with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy or C(=O)R
7
; NR
5
R
6
; phenyl or R
10

either of which can be unsubstituted or substituted optionally with OH,
(CH
2
)
n
NR
5
R
6
, halogen, C
1-4
 alkoxy, C
1-4
 haloalkoxy, C(=O)R
7
, S(=O)
m
R
8
 or
SO
2
NR
5
R
6
, wherein m is 0 - 2 and n is 0 - 2;

Provided that when G is SO
2
 and R
3
 is in the 4 position and is H or halogen then R
1

and R
2
 are not H, C
1-6
 alkyl substituted optionally with OH, C
1-6
 alkoxy, C
2-6

alkoxycarbonyl, C
2-6
 alkenyl, phenyl, phenoxy, pyridyl, tetrahydrofuryl, C
2-6

alkanoyl, C
2-6
 alkenyl, nor are they joined to form a 5, 6 or 7 member ring,
saturated or unsaturated, comprised of atoms selected optionally from C, O, S,

N in which said nitrogen, when saturated, is substituted optionally with H or
C
1-6
 alkyl or in which said carbon is substituted optionally with C
1-6
 alkyl, C
1-6

alkoxy or OH; and when R
3
 is in the 5 position and is H, Cl, Br, or C
1-3
 alkyl,
then neither R
1
 nor R
2
 can be H or C
1-4
 alkyl; and when G is C(=O) and in
the 5- position and R
3
 is H, then R
1
 and R
2
 cannot both be CH
3
;

R
5
 
&
 R
6
are the same or different and are: H; C
1-4
 alkyl; C
2-4
 alkyl substituted
optionally with OH, halogen, C
1-4
 alkoxy or C(=O)R
7
; C
1-4
 alkoxy; C
2-4
 alkoxy
substituted optionally with OH, halogen, C
1-4
 alkoxy or C(=O)R
7
; C
3-7
 alkenyl 
unsubstituted or substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy; C
3-7

alkynyl unsubstituted or substituted optionally with OH, NR
5
R
6
, or C
1-4
 alkoxy;
C
1-2
alkyl-C
3-5
cycloalkyl; C(=O)R
7
 or R
5
 and R
6
 can be joined to form a ring of
5 or 6 atoms selected from O, S, C or N, such as, pyrrolidine, oxazolidine,

thiomorpholine, thiomorpholine 1.1 dioxide, morpholine, piperazine or
thiazolidine 1,1-dioxide, which can be unsubstituted or substituted optionally on

carbon with OH, (=O), halogen, C
1-4
 alkoxy, C(=O)R
7
, C
1-6
 alkyl, C
1-6
 alkyl
substituted optionally with OH, halogen, C
1-4
 alkoxy, C(=O)R
7
 or on nitrogen
with C
1-4
 alkoxy, C(=O)R
7
, S(=O)
m
R
8
, C
1-6
 alkyl or C
2-6
 alkyl substituted
optionally with OH, halogen, C
1-4
 alkoxy, C(=O)R
7
 or on sulfur by (=O)
m
,
wherein m is 0 - 2;
R
7
 is:
C
1-8
 alkyl; C
1-8
 alkyl, substituted optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy
or C(=O)R
9
; C
1-4
 alkoxy; C
2-4
 alkoxy substituted optionally with OH, NR
5
R
6
,
halogen or C
1-4
 alkoxy; NR
5
R
6
; or phenyl or R
10
 either of which can be
unsubstituted or substituted optionally with OH, halogen, C
1-3
 alkyl, C
1-3

haloalkoxy, (CH
2
)
n
NR
5
R
6
, S(=O)
m
R
8
 or SO
2
NR
5
R
6
, wherein n is 0 or 1 and m
is 0-2;
R
8
 is:
C
1-4
 alkyl; C
2-4
 alkyl substituted optionally with OH, NR
5
R
6
, halogen, C
1-4
 alkoxy
or C(=O)R
7
;
R
9
 is:
C
1-4
 alkyl; C
1-4
 alkoxy; amino, C
1-3
 alkylamino, or di-C
1-3
 alkylamino;
R
10
 is:
a monocyclic ring system of 5 or 6 atoms composed of C, N, O, and/or S, such
as furan, thiophene, pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole,

isoxazole, isothiazole, thiazole, thiadiazole, pyridine, pyrimidine, pyridazine, and
pyrazine; and
G is:
C(=O) or SO
2
 or
wherein
the carbonic anhydrase inhibitor is (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno[2,3-b]thiopyran-2-sulfonamide

7,7-dioxide for the
preparation of a medicament for the treatment of

glaucoma and ocular hypertension.
Use of claim 21, wherein the carbonic anhydrase
inhibitor is selected from the group consisting of: (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-ethylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxy)propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-2-(3-methoxy)propyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-3,4-Dihydro-4-ethylamino-2-[2-methoxyethoxy)ethyl]
-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-Dihydro-2-[2-methoxyethoxy)ethyl]-4-propylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide;

(R)-3,4-Dihydro-4-ethylamino-2-[3-(2-methoxy)ethoxy]propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-3,4-Dihydro-2-[3-(methoxyethoxy)propyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide;

(R)-3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-Dihydro-4-ethylamino-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-4-Ethylamino-2-(4-methoxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioixide; (R)-4-Ethylamino-2-(4-hydroxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenylmethyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 
1,1-dioxide;

(R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenylmethyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-Ethylamino-3,4-dihydro-2-(2-methylpropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-4-Ethylamino-3,4-dihydro-2-(6-hydroxyhexyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-3,4-Dihydro-2-(3-hydroxypropyl)-4-(2-methylpropyl)amino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; and (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]
thiopyran-2-sulfonamide
7,7-dioxide.
Use of claim 21, wherein the carbonic anhydrase inhibitor is
selected from the group consisting of: (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxy)propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide

and (R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide; (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]thiopyran-2-sulfonamide

7,7-dioxide.
Use of claim 21, wherein the carbonic anhydrase
inhibitor is selected from the group consisting of: (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-ethylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-(2-ethoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2- ( 3-methoxy) propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-(3-methoxy)propyl-4-propylamino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide

hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2-[2-methoxyethoxy)ethyl]-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-[2-methoxyethoxy)ethyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide
hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2-[3-(2-methoxy)ethoxy]
propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 

1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-[3-(methoxyethoxy)propyl]
-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride;

(R)-3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-3,4-Dihydro-4-ethylamino-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide;
(R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide; (R)-4-Ethylamino-2-(4-methoxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-4-Ethylamino-2-(4-hydroxyphenyl)-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-hydroxyphenylmethyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide

hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(3-methoxyphenylmethyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(2-methylpropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide
hydrochloride; (R)-4-Ethylamino-3,4-dihydro-2-(6-hydroxyhexyl)-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride; (R)-3,4-Dihydro-2-(3-hydroxypropyl)-4-(2-methylpropyl)amino-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride hemihydrate; and (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]
thiopyran-2-sulfonamide
7,7-dioxide.
Use of claim 21, wherein the carbonic anhydrase inhibitor is
selected from the group consisting of: (R)-3,4-Dihydro-4-ethylamino-2-(3-methoxy)propyl-2H-thieno[3,2-e]
-1,2-thiazine-6-sulfonamide
1,1-dioxide hydrochloride

and (R)-3,4-Dihydro-4-ethylamino-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide hydrochloride; (R)-4-ethylamino-3,4-dihydro-2-(4-methoxy)butyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 

1,1-dioxide; (R)-3,4-dihydro-2-(4-methoxy)butyl-4-propylamino-2-thieno[3,2-e]-1,2-thiazine-6-sulfonamide

1,1-dioxide: (-)-trans-5,6-dihydro-6-(3-methoxy)propyl-4-propylamino-4H-thieno-[2,3-b]thiopyran-2-sulfonamide

7,7-dioxide.
Use of any of claims 21 to 25, wherein the beta-blocker
is selected from the racemic and enantiomeric forms of:

betaxolol, timolol, metoprolol, befunolol, falintolol,
levobunolol, carteolol, mepindolol, pindolol, bisoprolol, bopindolol, atenolol,

arotinolol, acebutolol, nadolol, celiprolol, metipranolol, bevantolol, ICI 118,551,
pamatolol, penbutolol, toliprolol, tiprenolol, practolol, procinolol, exaprolol,

cicloprolol, carazolol, tazolol, tienoxolool, oxprenolol, propranolol, IPS 339, labetolol,
dilevalol, esmolol, bupranolol, bunolol, isoxaprolol, diacetolol and hydroxylevobunolol,

and their pharmaceutically acceptable salts.
Use of claim 26, wherein the beta-blocker is selected
from the group consisting of: betaxolol, timolol, carteolol,

levobunolol and hydroxylevobunolol, and their
pharmaceutically acceptable salts.
Use of any of claims 21 to 27, wherein the beta-blocker
is a thiadiazole of formula:



and optically active isomers and pharmacologically acceptable salts thereof, wherein
R'' is selected from the group consisting of: hydrogen, halogen, C
1-5
 alkyl, C
2-5
 mono-alkenyl,
C
2-5
 alkoxy, C
3-6
 cycloalkyl, phenyl, phenalkyl, morpholino, furyl, thienyl and
pyrryl.
Use of claim 28, wherein R'' is selected from the group
consisting of: chlorine, ethyl, allyl, cyclopropyl, ethoxy,

phenyl, phenyl-chloromethyl and 2- (cyclopropylmethoxy)ethyl.
</CLAIMS>
</TEXT>
</DOC>
